Faeth Therapeutics, a clinical-stage biotechnology company pioneering metabolism-based cancer therapies, announced a $25 million strategic financing round to advance its lead program, PIKTOR, in endometrial cancer.

The raise brings Faeth's total funding to $92 million and will support the company's expansion across oncology and metabolic diseases. The funding round was led by S2G Ventures with participation from existing investors Khosla Ventures, Future Ventures, Digitalis Ventures, KdT Ventures, and Cantos, as well as new investors B Capital Group, Avicella, and THO Seed Fund.